U.S., Dec. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07269782) titled 'A Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Combination With Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC' on Nov. 26.
Brief Summary: The study is being conducted to to explore the reasonable dosage and evaluate the efficacy and safety of HLX43 (Anti-PD-L1 ADC) in Combination with Serplulimab (Anti-PD-1 Recombinant Humanized Monoclonal Antibody) as Neoadjuvant Therapy in Subjects with Non-Small Cell Lung Cancer (NSCLC)
Study Start Date: Jan. 20, 2026
Study Type: INTERVENTIONAL
Condition:
Non Small Cell Lung Cancer
Intervention:
DRUG: HLX43 DOSE 1
HLX43 is an anti-PD-L1 monoclonal antibody conj...